Amgen aims to discover, develop, and deliver transformative medicines to address some of the leading causes of death and disability worldwide, working to meet the needs of as many patients as possible. Conducting our research and development activities in accordance with our internal policies and external standards helps to ensure the integrity of and confidence in our trial results and, ultimately, in medicines approved for use. It also helps inspire confidence among potential clinical trial participants, increasing the likelihood of their enrollment in studies.

Clinical Research and Development

The rights, dignity, safety, and well-being of clinical trial participants are critical to the effective conduct of Amgen clinical trials. To that end, our Global Code of Ethics governs the design and conduct of Amgen-sponsored trials. Our high standards meet or exceed applicable local laws as well as widely accepted international regulatory standards.

Animal Research at Amgen

Amgen is committed to ethical practices in animal research. We acknowledge that while animal testing is often necessary for supporting the safety and efficacy of new medicines, consistent with local and international regulations, we prioritize ethical standards in every aspect of animal research. Amgen follows the principles of Reduction, Refinement and Replacement (the "3 Rs"), aiming to minimize the number of animals used, improve procedures to enhance animal welfare and actively pursue alternatives to animal testing wherever feasible. Read more in the section on Amgen's Commitment to the Ethical Use of Animals in Research.

Use of Stem Cells

Amgen is committed to the ethical use of stem cells in research to help unlock new scientific insights, model complex diseases, screen new compounds, and identify novel medicines. Read more in our Position Statement on Stem Cell Research.

Biobanking of Human Samples

Human samples play a vital role in Amgen's research, including helping to predict the safety and effectiveness of potential new therapies and identify people most or least likely to benefit from these therapies.

Policies